Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
53 participants
OBSERVATIONAL
2005-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Study hypothesis: malaria patients should exhibit a different pattern of enhancement, particularly when quantitative measurements of the SU signals is performed with destruction reperfusion kinetics.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Three cohortes will be studied: cohorte 1 infection at Plasmodium falciparum (24 patients), cohorte 3 infection at Plasmodium vivax, ovale or malariae (5 patients) and cohorte 2 other infectious diseases such as acute pyelonephritis (24 patients).
Study hypothesis: malaria patients should exhibit a different pattern of enhancement, particularly when quantitative measurements of the SU signals is performed with destruction reperfusion kinetics.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
DEFINED_POPULATION
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age over 18
* acute malaria infection or other infectious diseases
* Inpatients
* Signed informed consent form
Exclusion Criteria
* Criteria of bad tolerance of infection
* Treatment started for more than 8 hours
* Lack of cooperation
* History of splenectomy, hematological disease, cirrhosis with portal hypertension, splenomegaly
* Medical treatment with beta blocker, diuretic, immunodepression drugs
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assistance Publique - Hôpitaux de Paris
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jean-Michel Correas, MD PhD
Role: PRINCIPAL_INVESTIGATOR
NECKER UNIVERSITY HOSPITAL
Pierre Buffet, MD PhD
Role: STUDY_DIRECTOR
Centre Médical - Institut Pasteur
Olivier Lortholary, MD PhD
Role: STUDY_DIRECTOR
NECKER UNIVERSITY HOSPITAL
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Adult Radiology, Necker University Hospital
Paris, Île-de-France Region, France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Jean-Michel Correas, MD PhD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
04 025
Identifier Type: -
Identifier Source: org_study_id